Neuland Laboratories appoints Saharsh Davuluri as CEO & MD effective April 1, 2026, succeeding Sucheth Davuluri.
Sucheth Davuluri transitions to Executive Vice Chairman; contract services revenues tripled over last three years.
Company committed to four-phase peptide capacity expansion and doubling process development capabilities as a CDMO.
Neuland operates three US FDA-inspected facilities with 1218 KL capacity and 20+ commercial contracts globally.